Bisphosphonates in periodontal treatment: A review

Oral Health and Preventive Dentistry

Volumn 7, Issue 1, 2009, Pages 03-12

  Badran, Zahi ^a   Kraehenmann, Michael Alexander ^b   Guicheux, Jérôme ^a   Soueidan, Assem ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Bisphosphonates; Experimental periodontitis; Host modulation; Periodontal treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ENZYME INHIBITOR;

ANIMAL; DRUG EFFECT; HUMAN; OSTEOCLAST; OSTEOLYSIS; PERIODONTITIS; REVIEW;

ALVEOLAR BONE LOSS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ENZYME INHIBITORS; HUMANS; OSTEOCLASTS; PERIODONTITIS;

EID: 68049102131     PISSN: 16021622     EISSN: 17579996     Source Type: Journal    
DOI: 10.3290/j.ohpd.a15261     Document Type: Review

References (93)

1. AAOMS Position Paper. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-376.
2. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41(6): 326-331.
3. Alencar VB, Bezerra MM, Lima V, Abreu AL, Brito GA, Rocha FA et al. Disodium chlodronate prevents bone resorption in experimental periodontitis in rats. J Periodontol 2002; 73(3):251-256.
4. Axelsson P, Lindhe J. Effect of controlled oral hygiene procedures on caries and periodontal disease in adults. Results after 6 years. J Clin Periodontol 1981;8(3): 239-248.
5. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000; 71(8):1236-1240.
6. Blair HC, Athanasou NA. Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 2004;19(1):189-199.
7. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 1996;271(21): 12517-12524.
8. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423(6937):337-342.
9. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of a bisphosphonate on experimental periodontitis in monkeys. J Periodontol 1992;63(10): 825-830.
10. Buduneli E, Buduneli N, Vardar-Sengul S, Kardesler L, Atilla G, Lappin D et al. Systemic low-dose doxycycline and alendronate administration and serum interleukin-1 beta, osteocalcin, and C-reactive protein levels in rats. J Periodontol 2005;76(11):1927-1933.
11. Buduneli E, Vardar-Sengul S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of lowdose doxycycline and alendronate. J Periodontol 2007; 78(1):127-134.
12. Buduneli E, Vardar S, Buduneli N, Berdeli AH, Turkoglu O, Baskesen A et al. Effects of combined systemic administration of low-dose doxycycline and alendronate on endotoxin-induced periodontitis in rats. J Periodontol 2004;75(11):1516-1523.
13. D'Aoust P, McCulloch CA, Tenenbaum HC, Lekic PC. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell Tissue Res 2000; 302(3):353-363.
14. David P, Nguyen H, Barbier A, Baron R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res 1996;11(10): 1498-1507.
15. Denissen H, van Beek E, Lowik C, Papapoulos S, van den Hooff A. Ceramic hydroxyapatite implants for the release of bisphosphonate. Bone Miner 1994;25(2):123-134.
16. Denissen H, van Beek E, Martinetti R, Klein C, van der Zee E, Ravaglioli A. Net-shaped hydroxyapatite implants for release of agents modulating periodontal-like tissues. J Periodontal Res 1997;32(1 Pt 1):40-46.
17. Duarte PM, de Assis DR, Casati MZ, Sallum AW, Sallum EA, Nociti FH Jr. Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. J Periodontol 2004;75(9):1196-1202.
18. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007;4(1):42-55.
19. El-Shinnawi UM, El-Tantawy SI. The effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 2003;5(1):5-10.
20. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116(1):115-120.
21. Felsenberg D, Hoffmeister B, Michael Amling M. Bisphosphonattherapie assoziierte. Kiefernekrosen. Deutsches Arzteblatt 2006;46:A3078-A3080.
22. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96(1):133-138.
23. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4(1):30-34.
24. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004;3(5):401-416.
25. Goya JA, Paez HA, Mandalunis PM. Effect of topical administration of monosodium olpadronate on experimental periodontitis in rats. J Periodontol 2006;77(1):1-6.
26. Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum HC. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 1995;16(Suppl 4): 317S-327S.
27. Guenther HL, Guenther HE, Fleisch H. The effects of 1-hydroxyethane-1, 1-diphosphonate and dichloromethanediphosphonate on collagen synthesis by rabbit articular chondrocytes and rat bone cells. Biochem J 1981;196(1): 293-301.
28. Guicheux J, Soueidan A, Bouler J-M, Bujol B, Janvier P. Calcium phosphate biomaterial for the delivery of antiosteoporotic drugs. Drug Discovery Today 2005; 10(2):156, 157.
29. Gun-Il Im, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25(18):4105-4115.
30. Heymann D, Guicheux J, Gouin F, Passuti N, Daculsi G. Cytokines, growth factors and osteoclasts. Cytokine 1998;10(3):155-168.
31. Heymann D, Ory B, Gouin F, Green JR, Redini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004;10(7):337-343.
32. Hoefert S, Wierich W, Eufinger H, Krempien B. BP-associated avascular necrosis (AN) of the jaws: histological findings. Bone 2006;38(3):76.
33. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83(6):1930-1935.
34. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10(10):1478-1487.
35. Josse S, Faucheux C, Soueidan A, Grimandi G, Massiot D, Alonso B et al. Novel biomaterials for bisphosphonate delivery. Biomaterials 2005;26(14):2073-2080.
36. Kalpidis CD, Ruben MP. Treatment of intrabony periodontal defects with enamel matrix derivative: a literature review. J Periodontol 2002;73(11):1360-1376.
37. Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in periodontal diseases. Periodontol 2000 2006;40:144-163.
38. Kornman KS. Host modulation as a therapeutic strategy in the treatment of periodontal disease. Clin Infect Dis 1999;28(3):520-526.
39. Lam DK, Sandor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73(5):417-422.
40. Lane N, Armitage GC, Loomer P, Hsieh S, Majumdar S, Wang HY et al. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol 2005;76(7):1113-1122.
41. Lekovic V, Camargo PM, Klokkevold PR, Weinlaender M, Kenney EB, Dimitrijevic B et al. Preservation of alveolar bone in extraction sockets using bioabsorbable membranes. J Periodontol 1998;69(9):1044-1049.
42. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone February 1996;18(2):75-85.
43. Lindhe J, Nyman S. Scaling and granulation tissue removal in periodontal therapy. J Clin Periodontol 1985;12(5): 374-388.
44. Loee H, Theilade E, Jensen SB. Experimental gingivitis in man. J Periodontol 1965;36:177-187.
45. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13(11): 1668-1678.
46. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13(4):581-589.
47. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-1117.
48. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11): 1567-1575.
49. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3Hetidronate in rat and mouse bones. Bone 1996; 19(3):281-290.
50. Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and incidence of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-423.
51. McClung M. Bisphosphonates. Arq Bras Endocrinol Metabol 2006;50(4):735-744.
52. Menezes AM, Rocha FA, Chaves HV, Carvalho CB, Ribeiro RA, Brito GA. Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats. J Periodontol 2005;76(11):1901-1909.
53. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21(22):4253-4254.
54. Mitsuta T, Horiuchi H, Shinoda H. Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. J Periodontol 2002;73(5):479-486.
55. Nesbitt S, Nesbit A, Helfrich M, Horton M. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha versus beta 3, alpha 2 beta 1, and alpha versus beta 1 integrins. J Biol Chem 1993; 268(22):16737-16745.
56. O'Uchi N, Nishikawa H, Yoshino T, Kanoh H, Motoie H, Nishimori E et al. Inhibitory effects of YM175, a bisphosphonate, on the progression of experimental periodontitis in beagle dogs. J Periodontal Res 1998;33(4):196-204.
57. Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1997;14:216-248.
58. Pahlavan PS. Paget's disease of the bone. Saudi Med J 2000;21(4):404-405.
59. Parfitt AM. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55(3):273-286.
60. Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol 2007; 38(4):527-536.
61. Pastor Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Perez A, Sebastian-Lopez C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. Med Oral Patol Oral Cir Bucal 2006;11(1):E76-E79.
62. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003;8(1):12-37.
63. Reddy MS, Weatherford TW 3rd, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturallyoccurring periodontitis in beagle dogs. J Periodontol 1995;66(3):211-217.
64. Rocha M, Nava LE, Vazquez de la Torre C, Sanchez-Marin F, Garay-Sevilla ME, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol 2001;72(2): 204-209.
65. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-388.
66. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24(Suppl 5):73S-79S.
67. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(Suppl 12): 2961-2978.
68. Rousselle AV, Heymann D. Osteoclastic acidification pathways during bone resorption. Bone 2002;30(4):533-540.
69. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150-S162.
70. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35(10):801-803.
71. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88(6):2095-2105.
72. Saunders Y, Ross JR, Broadley KE, Edmonds PM, Patel S. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliat Med 2004;18(5):418-431.
73. Serhan CN. Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases? Expert Opin Ther Targets 2004;8(6):643-652.
74. Seymour GJ, Gemmell E, Westerman B, Cullinan M. Periodontics into the 21st century. Ann R Australas Coll Dent Surg 1996;13:71-78.
75. Shibutani T, Inuduka A, Horiki I, Luan Q, Iwayama Y. Bisphosphonate inhibits alveolar bone resorption in experimentally-induced peri-implantitis in dogs. Clin Oral Implants Res 2001;12(2):109-114.
76. Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J Periodontal Res 1995;30(4):277-284.
77. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18(1):25-34.
78. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 1992;63(Suppl 4):322-331.
79. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25(2):134-144.
80. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 2006;77(4): 738-743.
81. Takaishi Y, Ikeo T, Miki T, Nishizawa Y, Morii H. Suppression of alveolar bone resorption by etidronate treatment for periodontal disease: 4-to 5-year follow-up of four patients. J Int Med Res 2003;31(6):575-584.
82. Takaishi Y, Miki T, Nishizawa Y, Morii H. Clinical effect of etidronate on alveolar pyorrhoea associated with chronic marginal periodontitis: report of four cases. J Int Med Res 2001;29(4):355-365.
83. Takeyamaa S, Ito M, Shinoda H. A novel bisphosphonate, TRK-530, for periodontitis. Bone 2006;38(3):31-31.
84. Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, Sugaya A et al. Inhibitory effects of incadronate on the progression of rat experimental periodontitis by porphyromonas gingivalis infection. J Periodontol 2003;74(5): 603-609.
85. Teitelbaum SL, Bates M. Relationships of static and kinetic histomorphometric features of bone. Clin Orthop Relat Res 1980;(146):239-245.
86. Tenenbaum HC, Shelemay A, Girard B, Zohar R, Fritz PC. Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic/diagnostic uses. J Periodontol 2002;73(7): 813-822.
87. Tenenbaum HC, Torontali M, Sukhu B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 1992;13(3):249-255.
88. Twiss IM, Burggraaf J, Schoemaker RC, van Elburg RM, den Hartigh J, Cohen AF et al. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 2001;69(6):431-437.
89. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, Chaves E et al. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 1994;29(1):35-40.
90. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-1061.
91. Yaffe A, Binderman I, Breuer E, Pinto T, Golomb G. Disposition of alendronate following local delivery in a rat jaw. J Periodontol 1999;70(8):893-895.
92. Yaffe A, Iztkovich M, Earon Y, Alt I, Lilov R, Binderman I. Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997;68(9):884-889.
93. Yamaguchi K, Motegi K, Iwakura Y, Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol 2000;130(7): 1646-1654.